Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Phase II study of neoadjuvant treatment with Gemcitabine, Tarceva and Oxaliplatin followed by
chemotherapy with Tarceva and Gemcitabine in patients with pancreatic adenocarcinoma with
borderline resectability. The primary objective is to determine the resectability rate of
patients with pancreas adenocarcinoma with borderline resectability determined
radiologically, treated with Gemcitabine, Tarceva and Oxaliplatin followed by radiotherapy
with Gemcitabine and Tarceva.